Ligand Pharmaceuticals Analyst Ratings
Ligand Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/21/2022 | 55.14% | Barclays | $150 → $120 | Maintains | Overweight |
| 10/25/2022 | 93.92% | Barclays | $157 → $150 | Maintains | Overweight |
| 09/02/2022 | 126.24% | Roth Capital | $185 → $175 | Maintains | Buy |
| 07/05/2022 | 102.97% | Barclays | $165 → $157 | Maintains | Overweight |
| 05/16/2022 | 68.07% | Stephens & Co. | $153 → $130 | Maintains | Overweight |
| 02/22/2022 | 68.07% | Benchmark | $180 → $130 | Maintains | Buy |
| 02/18/2022 | 113.32% | Barclays | $185 → $165 | Maintains | Overweight |
| 09/22/2021 | 132.71% | Barclays | $174 → $180 | Maintains | Overweight |
| 07/30/2021 | 145.64% | Roth Capital | $200 → $190 | Maintains | Buy |
| 05/04/2021 | 145.64% | Barclays | $198 → $190 | Maintains | Overweight |
| 02/04/2021 | 155.98% | Barclays | $145 → $198 | Maintains | Overweight |
| 02/04/2021 | 158.56% | Roth Capital | $195 → $200 | Maintains | Buy |
| 02/04/2021 | 300.78% | HC Wainwright & Co. | $229 → $310 | Maintains | Buy |
| 10/21/2020 | 152.1% | Craig-Hallum | $215 → $195 | Maintains | Buy |
| 09/29/2020 | 152.1% | Roth Capital | $190 → $195 | Reiterates | → Buy |
| 08/04/2020 | 87.46% | Barclays | $134 → $145 | Maintains | Overweight |
| 04/08/2020 | 196.06% | HC Wainwright & Co. | $237 → $229 | Maintains | Buy |
| 03/24/2020 | — | Argus Research | Downgrades | Buy → Hold | |
| 03/10/2020 | — | Guggenheim | Initiates Coverage On | → Neutral | |
| 02/06/2020 | — | Benchmark | Initiates Coverage On | → Buy | |
| 09/19/2019 | 70.65% | Barclays | $110 → $132 | Upgrades | Equal-Weight → Overweight |
| 08/05/2019 | 42.21% | Barclays | $131 → $110 | Maintains | Equal-Weight |
| 06/11/2019 | 69.36% | Barclays | → $131 | Initiates Coverage On | → Equal-Weight |
| 09/19/2018 | 249.06% | HC Wainwright & Co. | $257 → $270 | Maintains | Buy |
| 08/17/2018 | 230.96% | Goldman Sachs | → $256 | Initiates Coverage On | → Neutral |
| 08/08/2018 | — | Roth Capital | Downgrades | Buy → Neutral | |
| 06/21/2018 | 236.13% | Argus Research | → $260 | Initiates Coverage On | → Buy |
| 03/07/2018 | 135.29% | HC Wainwright & Co. | $170 → $182 | Maintains | Buy |
| 01/24/2018 | 119.78% | HC Wainwright & Co. | $159 → $170 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 11/21/2022 | 55.14% | 巴克莱 | $150 → $120 | 维护 | 超重 |
| 10/25/2022 | 93.92% | 巴克莱 | $157 → $150 | 维护 | 超重 |
| 09/02/2022 | 126.24% | 罗斯资本 | $185 → $175 | 维护 | 买 |
| 07/05/2022 | 102.97% | 巴克莱 | $165 → $157 | 维护 | 超重 |
| 05/16/2022 | 68.07% | 斯蒂芬斯公司 | $153 → $130 | 维护 | 超重 |
| 02/22/2022 | 68.07% | 基准 | $180 → $130 | 维护 | 买 |
| 02/18/2022 | 113.32% | 巴克莱 | $185 → $165 | 维护 | 超重 |
| 09/22/2021 | 132.71% | 巴克莱 | $174 → $180 | 维护 | 超重 |
| 07/30/2021 | 145.64% | 罗斯资本 | $200 → $190 | 维护 | 买 |
| 05/04/2021 | 145.64% | 巴克莱 | $198 → $190 | 维护 | 超重 |
| 02/04/2021 | 155.98% | 巴克莱 | $145 → $198 | 维护 | 超重 |
| 02/04/2021 | 158.56% | 罗斯资本 | $195 → $200 | 维护 | 买 |
| 02/04/2021 | 300.78% | HC Wainwright公司 | $229 → $310 | 维护 | 买 |
| 10/21/2020 | 152.1% | 克雷格-哈勒姆 | $215 → $195 | 维护 | 买 |
| 09/29/2020 | 152.1% | 罗斯资本 | $190 → $195 | 重申 | →购买 |
| 08/04/2020 | 87.46% | 巴克莱 | $134 → $145 | 维护 | 超重 |
| 04/08/2020 | 196.06% | HC Wainwright公司 | $237 → $229 | 维护 | 买 |
| 03/24/2020 | — | Argus研究 | 评级下调 | 购买→Hold | |
| 03/10/2020 | — | 古根海姆 | 开始承保 | →中性 | |
| 02/06/2020 | — | 基准 | 开始承保 | →购买 | |
| 09/19/2019 | 70.65% | 巴克莱 | $110 → $132 | 升级 | 等重→超重 |
| 08/05/2019 | 42.21% | 巴克莱 | $131 → $110 | 维护 | 等重 |
| 06/11/2019 | 69.36% | 巴克莱 | → $131 | 开始承保 | →等重 |
| 09/19/2018 | 249.06% | HC Wainwright公司 | $257 → $270 | 维护 | 买 |
| 08/17/2018 | 230.96% | 高盛 | → $256 | 开始承保 | →中性 |
| 08/08/2018 | — | 罗斯资本 | 评级下调 | 购买→中性 | |
| 06/21/2018 | 236.13% | Argus研究 | → $260 | 开始承保 | →购买 |
| 03/07/2018 | 135.29% | HC Wainwright公司 | $170 → $182 | 维护 | 买 |
| 01/24/2018 | 119.78% | HC Wainwright公司 | $159 → $170 | 维护 | 买 |
What is the target price for Ligand Pharmaceuticals (LGND)?
Ligand PharmPharmticals(LGND)的目标价格是多少？
The latest price target for Ligand Pharmaceuticals (NASDAQ: LGND) was reported by Barclays on November 21, 2022. The analyst firm set a price target for $120.00 expecting LGND to rise to within 12 months (a possible 55.14% upside). 7 analyst firms have reported ratings in the last year.
巴克莱银行于2022年11月21日公布了纳斯达克(Ligand PharmPharmticals)的最新目标价。这家分析公司将目标价定为120.00美元，预计LGND将在12个月内上涨至55.14%(可能上涨55.14%)。去年有7家分析公司公布了评级。
What is the most recent analyst rating for Ligand Pharmaceuticals (LGND)?
Ligand PharmPharmticals(LGND)的最新分析师评级是多少？
The latest analyst rating for Ligand Pharmaceuticals (NASDAQ: LGND) was provided by Barclays, and Ligand Pharmaceuticals maintained their overweight rating.
巴克莱提供了对Ligand PharmPharmticals(纳斯达克代码：LGND)的最新分析师评级，Ligand PharmPharmticals维持其增持评级。
When is the next analyst rating going to be posted or updated for Ligand Pharmaceuticals (LGND)?
Ligand PharmPharmticals(LGND)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ligand Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ligand Pharmaceuticals was filed on November 21, 2022 so you should expect the next rating to be made available sometime around November 21, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Ligand制药公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Ligand制药的上一次评级是在2022年11月21日提交的，所以你应该预计下一次评级将在2023年11月21日左右的某个时候提供。
Is the Analyst Rating Ligand Pharmaceuticals (LGND) correct?
分析师对Ligand制药(LGND)的评级正确吗？
While ratings are subjective and will change, the latest Ligand Pharmaceuticals (LGND) rating was a maintained with a price target of $150.00 to $120.00. The current price Ligand Pharmaceuticals (LGND) is trading at is $77.35, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Ligand制药(LGND)评级保持不变，目标价在150.00美元至120.00美元之间。Ligand制药(LGND)目前的交易价格为77.35美元，超出了分析师的预测区间。